
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. is positioned favorably due to its focus on developing proprietary medicines for significant unmet medical needs in oncology and COVID-19 treatment, with promising candidates like Endoxifen and the inhaled and nasal spray formulations for COVID-19. The company exhibits an attractive current valuation, evident from the upward adjustments in price targets based on net present value (NPV) analyses, indicating strong potential for future growth. Additionally, the anticipated achievement of key clinical milestones is expected to act as a catalyst for stock performance, further enhancing the company's positive outlook.
Bears say
Atossa Therapeutics Inc reported a net loss of $8.7 million, with an earnings per share (EPS) of $(0.07), aligning with previous losses of $8.4 million and an EPS of $(0.07) in earlier periods. The company faces significant risks that could impede its ability to meet financial targets, including balance sheet and liquidity concerns, potential failures in demonstrating the safety and efficacy of its product candidates, and challenges related to regulatory approvals and commercialization. Additionally, external factors such as competition, macroeconomic fluctuations, and changing investor sentiments toward biotech stocks further contribute to the negative outlook on the company’s stock performance.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares